2025-12-19 - Analysis Report
Okay, let's break down this report on Intuitive Surgical (ISRG).

**0. Introduction**

This report analyzes the performance of Intuitive Surgical (ISRG) relative to the S&P 500 (VOO), examines its recent stock behavior, and considers analyst opinions and financial data to provide a comprehensive investment overview.

**1. Return Comparison and Alpha/Beta Analysis**

*   **Company Overview:** Intuitive Surgical Inc. is a company that designs, manufactures, and markets robotic-assisted surgical systems.
*   **ISRG Cumulative Return:** 107.68%
*   **VOO Cumulative Return:** 99.09%
*   **Divergence:** Current: 5.2.  The relative divergence of 31.5 indicates that the current divergence is in the lower end of its historical range (31.5% percentile).

**Alpha, Beta and Volatility Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 68.0% | 77.6% | 40.0% | -0.1 | 43.6 |
| 2016-2018  | 64.0% | 72.2% | 49.0% | -0.0 | 57.2 |
| 2017-2019  | 54.0% | 72.2% | 31.0% | 0.2 | 70.6 |
| 2018-2020  | -6.0% | 80.4% | -29.0% | 0.3 | 97.8 |
| 2019-2021  | 29.0% | 80.4% | -18.0% | 0.6 | 128.8 |
| 2020-2022  | -23.0% | 80.4% | -22.0% | 1.2 | 95.1 |
| 2021-2023  | -17.0% | 77.5% | -18.0% | 1.7 | 120.9 |
| 2022-2024  | 36.0% | 77.5% | 15.0% | 1.7 | 187.1 |
| 2023-2025  | 70.0% | 72.7% | 6.0% | 0.8 | 201.4 |

*   **Analysis:**

    *   **Cumulative Return & Divergence:** ISRG has outperformed the S&P 500 over the analyzed period. The current divergence is relatively low compared to its historical range.
    *   **CAGR (Compound Annual Growth Rate):** CAGR has fluctuated significantly, showing high growth periods (e.g., 2015-2017, 2016-2018, 2017-2019, 2023-2025) and periods of negative growth (2018-2020, 2020-2022, 2021-2023).
    *   **MDD (Maximum Drawdown):** High MDD values indicate significant volatility and risk.
    *   **Alpha:** Alpha has been both positive and negative, indicating periods of outperformance and underperformance relative to the market risk-free rate. Generally, recent values are negative.
    *   **Beta:** Beta values have increased over time, suggesting that ISRG has become more sensitive to market movements.
*    **Cap(B):** Market Cap has generally increased, reflecting growth, but has seen decreases in certain periods.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 561.89
*   **Last-market:** price': 561.89, 'previousClose': 556.86, 'change': 0.9
*   **5-day SMA:** 555.03
*   **20-day SMA:** 563.07
*   **60-day SMA:** 520.55

*   **Analysis:** The 5-day SMA is below the 20-day SMA, which is slightly below the current price indicating a short-term upward trend. The 60-day SMA is significantly lower than the 20-day SMA and current price, suggesting a longer-term upward trend.

**3. RSI, PPO, and Expected Return**

*   **MRI (Market Risk Indicator):** 0.7 (Medium Investment Recommended)
*   **RSI:** 43.00 (Neutral, neither overbought nor oversold)
*   **PPO:** -0.57 (Slightly negative, indicating potential short-term weakness)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent (20 days) relative divergence change:** 0.0 (단기하락) (Short-term decline)
*   **Expected Return (%):** 28.5%

*   **Analysis:**

    *   The MRI suggests a medium level of investment risk.
    *   The RSI suggests a slightly neutral condition, meaning the stock is not currently overbought or oversold.
    *   The PPO's negative value indicates that the short-term moving average is slightly below the long-term moving average, indicating potential short-term downward pressure.
    *   The Hybrid Signal indicates that a buying opportunity may be there, with strong potential.
    *   The expected return of 28.5% is very positive.

**4. Recent News & Significant Events**

*   **Key Headlines:**

    *   Analysts at Truist Financial Expect ISRG Stock Price to Rise, setting a $650 target.
    *   Reports highlight potential catalysts for 2026 and recent stock performance.
    *   Analysis compares ISRG to Medtronic (MDT) in the robotics space.
    *   Reports identify potential buying opportunities based on key support levels.

*   **Analysis:** Recent news is predominantly positive, with analyst upgrades, identification of catalysts for future growth, and recognition of ISRG's position in the robotics market.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.06)
*   **Target Price:** Average: 598.57, High: 700.00, Low: 378.00

*   **Analysis:** Analyst consensus is generally positive ("Buy" rating), with an average target price significantly above the current price.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-10-22 | 1.98 | 2.51 B$   |
| 2025-07-23 | 1.84 | 2.44 B$   |
| 2025-04-23 | 1.95 | 2.25 B$   |
| 2024-10-18 | 1.59 | 2.04 B$   |
| 2025-10-22 | 1.59 | 2.04 B$   |

*   **Analysis:** Both EPS (Earnings Per Share) and revenue have shown a positive trend in recent quarters, indicating solid growth. 2025-10-22 has the highest revenue and EPS.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $2.51B    | 66.36%       |
| 2025-06-30   | $2.44B    | 66.31%       |
| 2025-03-31   | $2.25B    | 64.69%       |
| 2024-12-31   | $2.41B    | 68.04%       |
| 2024-09-30   | $2.04B    | 67.41%       |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-09-30   | $16.93B   | 4.16%    |
| 2025-06-30   | $17.85B   | 3.69%    |
| 2025-03-31   | $17.11B   | 4.08%    |
| 2024-12-31   | $16.43B   | 4.17%    |
| 2024-09-30   | $15.58B   | 3.63%    |

*   **Analysis:**

    *   **Revenue:** Revenue has been steadily increasing.
    *   **Profit Margin:** Profit margins remain consistently high, indicating strong profitability and efficient operations.
    *   **Equity:** Equity has generally increased, reflecting growth in the company's net assets.
    *   **ROE (Return on Equity):** ROE is fairly consistent, showing a good return on shareholder equity.

**7. Comprehensive Analysis**

Intuitive Surgical (ISRG) presents a mixed but largely positive picture.

*   **Strengths:**

    *   **Outperformance:** ISRG has historically outperformed the S&P 500, although recent divergence is lower.
    *   **Growth:** Strong revenue and EPS growth in recent quarters.
    *   **Profitability:** High and consistent profit margins.
    *   **Analyst Sentiment:** Positive analyst consensus with price targets above the current price.
    *   **Favorable News:** Recent news highlights positive catalysts and analyst upgrades.
    *   **Technology:**  Dominant position in the robotic surgery market.
    *   **Financial health:** Good ROE and increasing Equity

*   **Weaknesses:**

    *   **Volatility:** High MDD indicates significant price swings.
    *   **Beta:** Increasing beta suggests increased sensitivity to market movements.
    *   **Short-term Weakness:** Slightly negative PPO suggests potential short-term downward pressure.
    *   **Historical Underperformance:** Negative Alpha values during certain periods indicates the company has underperformed vs. market risk-free rate.

*   **Overall:** ISRG is a growth-oriented company in a promising sector. While it exhibits volatility and some short-term weakness, the positive analyst sentiment, strong financial performance, and potential catalysts for future growth suggest a positive outlook. The "Medium Investment Recommended" MRI aligns with this assessment, suggesting that investors should proceed with a balanced approach, acknowledging both the potential rewards and the inherent risks. The recent buying signal warrants consideration.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.